Loading clinical trials...

COMPLETEDPHASE1

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20)

NCT01275131•Halozyme Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if recombinant human hyaluronidase PH20 (rHuPH20) will change the exposure and action of approved insulin analogs when given by continuous subcutaneous insulin infusion (CSII) in participants with Type 1 diabetes mellitus (T1DM). This study is divided into Stage 1, 2, and 3. Stage 3 was started chronologically before Stage 2 and, prior to performing Stage 2, the Sponsor made the decision to terminate Stage 2. Stage 2 was not initiated due to a strategic business decision and termination was not based on safety or efficacy concerns. No participants were enrolled in Stage 2.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male or female aged 18 to 65 years, inclusive. Females of child-bearing potential must use a standard and effective means of birth control for the duration of the study.
•2. Non-smoking participants with Type 1 diabetes mellitus (T1DM) treated with insulin for greater than or equal to 12 months. Non-smoking means abstinence from cigarettes and cigars for 3 months and negative cotinine screening tests.
•3. Body mass index (BMI) 18.0 to 35.0 kilograms per meter squared (kg/m\^2), inclusive.
•4. Glycosylated hemoglobin A1c (HbA1c) ≤10 % based on local laboratory results.
•5. Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL).
•6. Current treatment with insulin \<90 units per day (U/d).
•7. Routine use of continuous subcutaneous insulin infusion (CSII) as the primary route of insulin administration.
•8. Participant should be in good general health based on medical history and physical examination, without medical conditions that might prevent the completion of study drug infusions and assessments required in this protocol.

Exclusion Criteria

•1. Known or suspected allergy to any component of any of the study drugs in this trial.
•2. Previous enrollment in this trial (Exception: participants in Stage 1 are permitted to participate in Stage 2).
•3. Use of drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia. Participants taking maintenance doses of blood thinners (eg, Coumadin or heparin) will be excluded.
•4. Use of any long-acting insulin injection within 72 hours of Stage 1 or Stage 3.
•5. Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the Investigator.
•6. Current addiction to alcohol or substances of abuse as determined by the Investigator.
•7. Blood donation or phlebotomy (\>500 milliliters \[mL\]) within the previous 8 weeks of Screening. This applies both to new participants and to participants who have participated in Stage 1 and who wish to continue in Stage 2.
•8. Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device \[IUD\], oral or injectable contraceptives, or barrier methods).
•9. Symptomatic gastroparesis.
•10. Receipt of any investigational drug within 4 weeks of Stage 1 or Stage 2.

Locations (1)

Profil Institute for Clinical Research

Chula Vista, California, United States

Key Dates

Start Date

January 1, 2011

Primary Completion Date

December 1, 2011

Completion Date

December 1, 2011

Last Updated

July 25, 2014

Enrollment

ACTUAL participants

Conditions

Type 1 Diabetes Mellitus

Interventions

Insulin aspart

DRUG

Recombinant human hyaluronidase PH20 (rHuPH20)

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

NCT06390371

Type 1 Diabetes Mellitus

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 25, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)

The Effects of Fluoxetine and/or DHEA

Fake Carbs Practice With AID System - MiniMed 780G in Children and Adolescents With T1D.

The COCCOS Study: a Transition Program for Young Persons With Chronic Conditions

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy